Bayer has received approval from Health Canada for Eylea (aflibercept, solution for intravitreal injection) for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD). The approval is based on the results of two Phase III clinical studies, which demonstrated that aflibercept injection dosed every eight weeks, following three initial monthly injections, was non-inferior to ranibizumab injection dosed every four weeks. This was measured by the primary endpoint...